Last reviewed · How we verify
LXE408
At a glance
| Generic name | LXE408 |
|---|---|
| Sponsor | Drugs for Neglected Diseases |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. (PHASE2)
- A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis (PHASE2)
- LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study (PHASE2)
- A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LXE408 CI brief — competitive landscape report
- LXE408 updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI